Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New ablation strategy aims to keep hearts in rhythm longer

NCT ID NCT02150902

Disease control Sponsor: Ottawa Heart Institute Research Corporation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two catheter ablation techniques for atrial fibrillation (AF), a condition where the heart beats irregularly. One method uses a standard approach with a drug called adenosine to find missed spots, while the other adds an extra ring of ablation without the drug. Researchers want to see which method better prevents AF from coming back over 12 months. About 400 adults with paroxysmal AF are taking part across Canada.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

411 people

The number who actually took part.

Start date

Mar 2015

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥18 years 2. Subjects must have symptomatic Paroxysmal AF that is refractory to at least one class I or Class III antiarrhythmic medication OR be intolerant of antiarrhythmic medications OR prefer not to trial antiarrhythmic medications 3. At least one episode of AF documented on 12-lead ECG, Holter monitor or Loop recorder. 4. Subjects must be able to provide informed consent Exclusion Criteria: 1. Subjects with persistent or permanent AF 2. History of previous catheter or surgical ablation for AF 3. Presence of known intracardiac thrombus 4. Subjects with contraindication to systemic oral anticoagulation therapy, including a history of Heparin Induced Thrombocytopenia 5. Subjects with reversible causes of AF 6. Subjects with significant valve disease (moderate or severe mitral/aortic stenosis or regurgitation) 7. Subjects with known adverse reaction to adenosine 8. Subjects with congenital heart disease 9. Subjects that are pregnant

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrial fibrillation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atrial fibrillation paroxysmal atrial fibrillation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atrial fibrillation

Contacts and locations

Locations

  • CIUSSSNIM-Hopital du Sacre-Coeur de Montreal

    Montreal, Quebec, H4J 1C5, Canada

  • Centre hospitalier universitaire de Sherbrooke (CHUS)

    Sherbrooke, Quebec, J1H 5N4, Canada

  • Institut universitaire de cardiologie et de pneumologie de Quebec

    Québec, Quebec, G1V 4G5, Canada

  • McGill University Health Center

    Montreal, Quebec, H3G 1A4, Canada

  • QE II Health Sciences Centre

    Halifax, Nova Scotia, B3H 3A7, Canada

  • St. Michael"s Hospital

    Toronto, Ontario, M5B 1W8, Canada

  • Sunnybrook Health Sciences Centre

    Toronto, Ontario, Canada

  • Toronto General Hospital-University Health Network

    Toronto, Ontario, M5G 2C4, Canada

  • University of Calgary-Foothills Campus

    Calgary, Alberta, T2N 4Z6, Canada

  • University of Ottawa Heart Institute

    Ottawa, Ontario, K1Y 4W7, Canada

  • Victoria Cardiac Arrhythmia Trials Inc.

    Victoria, British Columbia, V8T 1Z4, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.